MADAM-6

MADAM-6
Names
Preferred IUPAC name
N-Methyl-1-(6-methyl-2H-1,3-benzodioxol-5-yl)propan-2-amine
Other names
6-Methyl-MDMA
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C12H17NO2/c1-8-4-11-12(15-7-14-11)6-10(8)5-9(2)13-3/h4,6,9,13H,5,7H2,1-3H3
    Key: CRQPDNIUPWXPNK-UHFFFAOYSA-N
  • C1(=CC2=C(C=C1CC(C)NC)OCO2)C
Properties
C12H17NO2
Molar mass 207.273 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

MADAM-6, or 2, N-dimethyl-4,5-methylenedioxyamphetamine, is a lesser-known recreational drug of the methamphetamine class, similar in structure to MDMA (ecstasy).[1] MADAM-6 was first synthesized by Alexander Shulgin.[2] In Shulgin's book PiHKAL, the minimum dosage is listed as greater than 280 mg, and the duration is unknown.[2] MADAM-6 produces few to no effects and Shulgin describes it as "not active".[2] Very little data exists about the pharmacological properties, metabolism, and toxicity of MADAM-6.

MADAM-6 has been studied for its potential antiparkinsonian effects.[3] However, no clinical trials suggest the drug is effective against Parkinson's disease.

  1. ^ Patt, M; Gündisch, D; Wüllner, U; Blocher, A; Kovar, K. -A; Machulla, H. -J (1999). "N-[11C]methyl-3,4-methylenedioxyamphetamine (Ecstasy) and 2-methyl-N-[11C]methyl-4,5-methylenedioxyamphetamine: Synthesis and biodistribution studies". Journal of Radioanalytical and Nuclear Chemistry. 240 (2): 535. doi:10.1007/BF02349410. S2CID 96272983.
  2. ^ a b c MADAM-6 entry in PiHKAL
  3. ^ US patent US2015025063, Caron; Gainetdinov & Sotnikova, "Antiparkinsonian Action Of Phenylisopropylamines", published 2014-09-30, issued 2015-01-22